Lazaros George, Vlachopoulos Charalambos, Lazarou Emilia, Tsioufis Konstantinos
First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, Vas. Sofias 114, 11528, Athens, Greece.
Curr Cardiol Rep. 2021 Jul 1;23(8):106. doi: 10.1007/s11886-021-01539-7.
Pericardial effusion is a challenging pericardial syndrome and a cause of serious concern for physicians and patients due to its potential progression to life-threatening cardiac tamponade. In this review, we summarize the contemporary evidence of the etiology; diagnostic work-up, with particular emphasis on the contribution of multimodality imaging; therapeutic options; and short- and long-term outcomes of these patients.
In recent years, an important piece of information has contributed to put together several missing parts of the puzzle of pericardial effusion. The most recent 2015 guidelines of the European Society of Cardiology for the diagnosis and management of pericardial diseases are a valuable aid for a tailored approach to this condition. Actually, current guidelines suggest a 4-step treatment algorithm depending on the presence or absence of hemodynamic impairment; the elevation of inflammatory markers; the presence of a known or first-diagnosed underlying condition, possibly related to pericardial effusion; and finally the duration and size of the effusion. In contrast to earlier perceptions, based on the most recent evidence, it seems that in the subgroup of asymptomatic patients with large (> 2-cm end-diastolic diameter), chronic (> 3 months) C-reactive protein negative, idiopathic (without an apparent cause) pericardial effusion, a conservative approach is the most reasonable option. At present there is an increasing interest in the pericardial syndromes in general and pericardial effusions in specific, which has consistently expanded our knowledge in this "hazy landscape." Apart from general recommendations applied to all cases, an individualized, etiologically driven treatment is of paramount importance.
心包积液是一种具有挑战性的心包综合征,由于其可能进展为危及生命的心脏压塞,一直是医生和患者严重关注的问题。在本综述中,我们总结了病因的当代证据;诊断检查,特别强调多模态成像的作用;治疗选择;以及这些患者的短期和长期预后。
近年来,一条重要信息有助于拼凑心包积液难题中几个缺失的部分。欧洲心脏病学会2015年最新的心包疾病诊断和管理指南是针对这种情况采取量身定制方法的宝贵辅助工具。实际上,当前指南提出了一种四步治疗算法,该算法取决于是否存在血流动力学损害;炎症标志物的升高;是否存在已知或首次诊断的潜在疾病,可能与心包积液有关;最后是积液的持续时间和大小。与早期的认识相反,基于最新证据,对于无症状、大(舒张末期直径>2cm)、慢性(>3个月)、C反应蛋白阴性、特发性(无明显病因)心包积液亚组患者,保守治疗似乎是最合理的选择。目前,人们对一般的心包综合征特别是心包积液的兴趣日益增加,这不断扩展了我们在这片“模糊领域”的知识。除了适用于所有病例的一般建议外,个体化的、病因驱动的治疗至关重要。